Immunotherapy: On the edge between experimental and clinical oncology

Journal of Chemotherapy

Volumn 13, Issue 1, 2001, Pages 15-23

  Fagnoni, F F ^a   Robustelli Della Cuna, G ^a  

^a IRCCS   (Italy)

Author keywords

Cancer; Immunotherapy; T lymphocytes

Indexed keywords

MONOCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; ALLOGENIC BONE MARROW TRANSPLANTATION; B CELL LYMPHOMA; BREAST CANCER; CANCER CHEMOTHERAPY; IMMUNE SYSTEM; REVIEW; SOLID TUMOR; T LYMPHOCYTE;

EID: 0035111132     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2001.13.1.15     Document Type: Review

References (83)

1. Immunology taught by viruses
2. Tumor immunity as autoimmunity: Tumor antigens include normal self proteins which stimulate anergic peripheral T cells
3. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
4. Tumors of the immunocompromised patient
5. Identifying strategies for immune intervention
6. Immunology: Improving on nature in the twenty-first century
7. Tumor Immunology: The glass is half full
8. Immunotherapy for cancer
9. Monoclonal antibody therapy of cancer
10. Continuous cultures of fused cells secreting antibody of predefined specificity
11. A monoclonal antibody defining a lymphoma-associated antigen in man
12. Antibody to molecularly-defined antigen confined to a tumor cell surface
13. Treatment of B cell lymphoma with monoclonal anti-idiotype antibody
14. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies
15. Genetic instabilities in human cancers
16. Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by anti-idiotype
17. Man-made antibodies
18. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
19. lDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
20. Humanization of an anti-p185HER2 antibody for human cancer therapy
21. Herceptin in the adjuvant setting: Phase III trials begin
22. Monoclonal antibody therapy for resected Dukes C colorectal cancer: Seven-year outcome of a multicenter randomized trial
23. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
24. Karnofsky Lecture: Immunotherapy of lymphoma
25. Principles for adoptive T cell therapy of human viral diseases
26. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
27. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
28. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr Virus-induced lymphoma in allogeneic transplant recipients
29. Treatment of relapsed Hodgking's disease using EBV-specific cytotoxic T cells
30. Prospects for adoptive T cell therapy
31. Bone-marrow transplantation
32. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts
33. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myelogenous leukemia
34. Adoptive immunotherapy with donor lymphocyte transfusions
35. Mechanisms of the graft-versus-leukemia reaction
36. Mini-allografts: Ongoing trials in humans
37. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
38. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect
39. Graft-versus-myeloma effect: Proof of principle
40. Nonmyeloablative stem cell transplantation and ceil therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
41. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
42. Cancer Vaccines
43. Cancer Vaccines
44. Viruses in human cancers
45. Hepatitis B virus: The major etiology of the hepatocellular carcinoma
46. Is vaccination against papillomavirus a possibility?
47. Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: Time to consider the Th1/Th2 paradigm
48. The great escape: Is immune evasion required for tumor progression?
49. Induction of anti-self-immunity to cure cancer
50. Selection of metastatic tumour phenotypes by host immune systems
51. Tumor antigens recognised by T lymphocytes
52. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses
53. Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL)
54. Dendritic cells in cancer immunotherapy
55. Dendritic cells and the control of immunity
56. Heterologous protection against influenza by injection of DNA encoding a viral protein
57. Exposing the immunology of naked DNA vaccines
58. DNA vaccines against cancer: From genes to therapy
59. Phenotypic analysis of antigen-specific T lymphocytes
60. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy
61. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy
62. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors
63. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long-term results of a clinical trial
64. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
65. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
66. DNA immunization induces protective immunity against B-cell lymphoma
67. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
68. Direct evidence to support the immunosurveillance concept in a human regressive melanoma
69. Clinical implications of cytogenetic abnormalities in melanoma
70. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
71. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
72. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
73. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
74. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
75. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial
76. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283
77. Treatment of solid tumors in children with tumour-lysate-pulsed dendritic cells
78. Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial
79. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial
80. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
81. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein
82. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation